Institutional members access full text with Ovid®

Vaccination of Cystic Fibrosis Patients Against Pseudomonas aeruginosa Reduces the Proportion of Patients Infected and Delays Time to Infection

Lang, Alois B. PhD*; Rüdeberg, Anna MD‡; Schöni, Martin H. MD‡; Que, John U. PhD†; Fürer, Emil PhD†; Schaad, Urs B. MD§

Pediatric Infectious Disease Journal: June 2004 - Volume 23 - Issue 6 - pp 504-510
Original Studies

Introduction: Cystic fibrosis (CF) almost always leads to chronic airway infection with Pseudomonas aeruginosa. Despite advances in antibiotic therapy, after chronic infection rapid deterioration in lung function occurs, increasing morbidity and mortality. Prevention of infection by vaccination is desirable, but earlier trials produced disappointing results. The promising short term immunogenicity and safety of a new P. aeruginosa vaccine prompted us to evaluate its long term efficacy. We conducted a 10-year retrospective analysis of outcomes in a group of vaccinated patients.

Materials and Methods: In 1989–1990, 30 young children with CF, mean age 7 years, with no prior history of infection with P. aeruginosa, were vaccinated against P. aeruginosa with a polyvalent conjugate vaccine. We report the follow-up of 26 of these patients from 1989 to 2001. The patients were given yearly vaccine boosters. Comparisons were made with a CF patient control group matched for gender, age and, where possible, genetic mutation. Vaccinated patients and controls were attending a single CF clinic and received the same clinical management throughout the study period. Main outcomes were time to infection, proportion of patients infected, development of P. aeruginosa mucoid phenotype, lung function and body weight.

Results: The time to infection with P. aeruginosa was longer in the vaccination group than in the control group, and fewer vaccinated patients than controls became chronically infected (32% versus 72%; P < 0.001). The proportion of mucoid infections was higher in the control group (44%) than in the vaccinated group (25%). Patients ≥18 years of age at the end of the study had a lower mean forced expiratory volume at 1 s (FEV1) than did those 13–17 years of age, but this difference was small in the vaccinated group (73.6% versus 83.7%) compared with the controls (48.0% versus 78.7%). In the ≥18 year age category the mean FEV1% at 10 years was 73.6% (vaccinated) and 48.0% (controls) (P < 0.05). In the vaccinated group only 11 (44%) of 25 patients were underweight at the 10-year follow-up compared with 18 (72%) of 25 at the beginning of the study. In the control group 17 (68%) of 25 patients were underweight at 10-year follow-up compared with 16 (64%) of 25 at the beginning of the study.

Conclusion: Regular vaccination of young CF patients for a period of 10 years with a polyvalent conjugate vaccine reduced the frequency of chronic infection with P. aeruginosa. This was associated with better preservation of lung function. Vaccinated patients gained more weight during the study period, a possible indication of an improved overall health status.

From*Research Immunology and †Research Bacteriology, Berna Biotech, Ltd., Bern, Switzerland; the ‡Department of Paediatrics, University of Bern, Bern, Switzerland; and the §Department of Paediatrics, University of Basel, Basel, Switzerland

Accepted for publication January 30, 2004.

Supported by a grant from Berna Biotech, Ltd., Berne, Switzerland. A.B.L., J.U.Q. and E.F. work in the Research Department of Berna Biotech, Ltd., Berne, Switzerland, where this Pseudomonas aeruginosa conjugate vaccine has been developed.

Reprints not available.

© 2004 Lippincott Williams & Wilkins, Inc.